Literature DB >> 12110427

Changes in gene expression associated with the bone anabolic effects of basic fibroblast growth factor in aged ovariectomized rats.

R A Power1, U T Iwaniec, T J Wronski.   

Abstract

Basic fibroblast growth factor (bFGF) stimulates bone formation in vitro and in vivo. The purpose of this study was to determine changes in gene expression for bone matrix proteins, growth factors, and cytokines associated with the stimulatory effects of bFGF on bone formation in aged ovariectomized (ovx) rats. At 3 months of age, female Sprague-Dawley rats were sham-operated (sham) or ovariectomized (ovx), then maintained untreated for 1 year. At 15 months of age, baseline (BSL) sham and ovx rats were killed. All other rats received daily intravenous injections of bFGF (200 microg/kg) or vehicle (veh) for 14 days. Lumbar vertebrae were processed for quantitative bone histomorphometry or molecular analyses. Ovariectomy decreased vertebral cancellous bone volume by approximately 33% and increased most indices of bone turnover. Treatment of aged ovx rats with bFGF for only 14 days significantly increased cancellous bone volume compared with vehicle treatment of ovx rats, but this variable remained lower than in sham + veh rats. Osteoid volume, osteoblast surface, and osteoid surface were markedly increased, and osteoclast surface was significantly decreased in ovx + bFGF rats compared with sham + veh and ovx + veh rats. Northern analyses revealed that mRNA levels for osteocalcin and type I collagen, relative to 18S RNA, were significantly higher in ovx + bFGF rats than in ovx + veh rats by a factor of >10. RNase protection assays revealed that insulin-like growth factor (IGF-I) mRNA levels, relative to L32 housekeeping gene, were also significantly higher, by nearly a factor of 3, in ovx + bFGF rats than in ovx + veh rats. Treatment of ovx rats with bFGF did not appear to affect message levels for transforming growth factor-beta (TGF-beta), interleukin-6 (IL-6), and interferon-gamma (IFN-gamma). These in vivo results suggest that bFGF treatment upregulates gene expression for IGF-I, which may mediate, at least in part, the increased gene expression for bone matrix proteins and the bone anabolic effects of bFGF in aged ovx rats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12110427     DOI: 10.1016/s8756-3282(02)00799-8

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

Review 1.  Molecular genetic studies of gene identification for osteoporosis: a 2004 update.

Authors:  Yong-Jun Liu; Hui Shen; Peng Xiao; Dong-Hai Xiong; Li-Hua Li; Robert R Recker; Hong-Wen Deng
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

2.  Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Authors:  Marja Hurley; Wei Yao; Nancy E Lane
Journal:  Osteoporos Int       Date:  2005-08-19       Impact factor: 4.507

3.  Proteomic analysis of gingival tissue and alveolar bone during alveolar bone healing.

Authors:  Hee-Young Yang; Joseph Kwon; Min-Suk Kook; Seong Soo Kang; Se Eun Kim; Sungoh Sohn; Seunggon Jung; Sang-Oh Kwon; Hyung-Seok Kim; Jae Hyuk Lee; Tae-Hoon Lee
Journal:  Mol Cell Proteomics       Date:  2013-07-03       Impact factor: 5.911

4.  Characterization of tunable FGF-2 releasing polyelectrolyte multilayers.

Authors:  Mara L Macdonald; Natalia M Rodriguez; Nisarg J Shah; Paula T Hammond
Journal:  Biomacromolecules       Date:  2010-08-09       Impact factor: 6.988

Review 5.  Gene expression studies of osteoporosis: implications for microarray research.

Authors:  V Dvornyk; R R Recker; H-W Deng
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

6.  Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats.

Authors:  R A Power; U T Iwaniec; K A Magee; N G Mitova-Caneva; T J Wronski
Journal:  Osteoporos Int       Date:  2004-03-30       Impact factor: 4.507

7.  In vitro and in vivo evidence for stimulation of bone resorption by an EP4 receptor agonist and basic fibroblast growth factor: Implications for their efficacy as bone anabolic agents.

Authors:  M E Downey; L S Holliday; J I Aguirre; T J Wronski
Journal:  Bone       Date:  2008-10-25       Impact factor: 4.398

8.  Inhibition of insulin-like growth factor-1 (IGF-1) expression by prolonged transforming growth factor-β1 (TGF-β1) administration suppresses osteoblast differentiation.

Authors:  Hiromi Ochiai; Shoko Okada; Akiko Saito; Kazuto Hoshi; Haruto Yamashita; Tsuyoshi Takato; Toshifumi Azuma
Journal:  J Biol Chem       Date:  2012-05-09       Impact factor: 5.157

9.  Polymorphisms in predicted miRNA binding sites and osteoporosis.

Authors:  Shu-Feng Lei; Christopher J Papasian; Hong-Wen Deng
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

10.  Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation.

Authors:  Xianmei Meng; David J Baylink; Matilda Sheng; Hongjie Wang; Daila S Gridley; K-H William Lau; Xiao-Bing Zhang
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.